Clinical Trial Update: Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating patidegib gel at 2% and 4% versus vehicle to reduce surgically eligible basal cell carcinomas in Basal Cell Nevus Syndrome (Gorlin sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Nevus Syndrome

Drugs mentioned

• Patidegib Gel 2% (patidegib)
• patidegib gel 4% (patidegib)

Snippet

Sponsor: PellePharm, Inc. | Conditions: Basal Cell Nevus Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-07-15